abstract: PURPOSE: We sought to present follow-up on 14 cases in which conchal cartilage graft was used to span small orbital floor defects (up to 2 x 2 cm). MATERIALS AND METHODS: Fourteen @entity1 with orbital floor blowout @entity174 were included in the study; in 8 cases, there was associated fracture of the inferior orbital rim. The decision to proceed surgically was based on the presence of at least one of the following conditions: @entity892 , @entity9577 , herniation of orbital tissues through gaps in the orbital floor bone, and concomitant displacement of bone fragments of the inferior orbital rim. Auricular cartilage was used in all cases. @entity2694 was via subtarsal incision unless a laceration was present and useable. RESULTS: The incidence of clinical signs during follow-up and the surgical complications found (1 case of entropion, 1 case of @entity4 ) are fully comparable with those reported in the literature; they do not appear to be correlated to the use of a cartilage graft. CONCLUSIONS: The use of auricular cartilage has wide application for small orbital floor defects. The conchal graft is easy to harvest. It provides an optimal support function for the globe with minimum donor-site morbidity. A graft of adequate size ensures adequate stability.

title: Treatment of orbital floor blowout XXXX with conchal auricular cartilage graft: a report on 14 cases.

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures']

entities_list: @entity9577 :: ('MESH:D015841', 'Disease') :: ['enophthalmos']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['palpebral edema']

entities_list: @entity2694 :: ('MESH:D009916', 'Disease') :: ['Access to the orbital floor']

entities_list: @entity892 :: ('MESH:D004172', 'Disease') :: ['diplopia']

answer: @entity174 :: (MESH:D050723,Disease) :: ['fractures']


abstract: UNASSIGNED: @entity1 with @entity146 , especially @entity1314 , often face low acceptance at work. This is particularly problematic when returning to work after sick leave, because it impedes reintegration into the former workplace. This study explores colleagues' reactions towards a problematic worker dependent on the returning @entity1 's reintegration strategy: The returning @entity1 undertaking changes in their behaviour is compared with the @entity1 requesting adjustments of the workplace. In an experimental study, 188 employed @entity1 read one of four vignettes that described a return-to-work-situation of a problematic co-worker. Across all vignettes, the co-worker was depicted as having previously caused problems in the work team. In the first vignette, the co-worker did not change anything (control condition) when she returned to work; in the second, she asked for workplace adjustments; in the third vignette she initiated efforts to change her own behaviour; and the fourth vignette combined both workplace adjustments and behavioural change. Study @entity1 were asked for their reactions towards the problematic co-worker. Vignettes that included a behavioural change evoked more positive reactions towards the co-worker than vignettes without any behavioural change. Asking for workplace adjustments alone did not yield more positive reactions compared to not initiating any change. When preparing employees with interactional problems for their return to work, it is not effective to only instruct them on their statutory entitlement for workplace adjustments. Instead, it is advisable to encourage them to proactively strive for behaviour changes.

title: Asking for work adjustments or initiating behavioural changes - what makes a 'problematic co-worker' score Brownie points? An experimental study on the reactions towards colleagues with a XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'person', 'persons', 'People']

entities_list: @entity1314 :: ('MESH:D010554', 'Disease') :: ['personality disorders']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['mental disorders']

answer: @entity1314 :: (MESH:D010554,Disease) :: ['personality disorder']


abstract: OBJECTIVE: @entity955 is a @entity74 commonly seen early after coronary artery bypass grafting, and it increases morbidity. METHODS: To investigate the effectiveness of @entity2399 in the prophylaxis of @entity955 , we conducted a prospective, randomized, placebo-controlled clinical study on 200 consecutive @entity1 in whom we performed elective and initial coronary artery bypass grafting operations. In each group 50% of @entity1 underwent beating-heart operations. In the treatment group 100 @entity1 (76 @entity1 and 24 @entity1 ; mean age, 57.63 +/- 9.68 years) received 24.34 mEq (3 g) of @entity2399 in 100 mL of saline solution that was administered over 2 hours (50 mL/h) preoperatively, perioperatively, and at postoperative days 0, 1, 2, and 3. In the control group 100 @entity1 (74 @entity1 and 26 @entity1 ; mean age, 59.96 +/- 9.29 years) received only 100 mL of saline solution according to the same administration schedule as the treatment group. RESULTS: @entity955 developed in 15 @entity1 from the treatment group and in 16 @entity1 from the control group. The @entity943 developed after 37.87 +/- 12.76 and 45.26 +/- 15.27 hours in the treatment and control groups, respectively. Although a significant relationship was found between low @entity2399 levels and increased incidence of @entity955 (P <.05), when the incidence of postoperative @entity955 is concerned, no significant difference was found between the 2 groups (P >.05). Also, no significant difference was found between operations with cardiopulmonary bypass and beating-heart operations in terms of @entity955 incidence (P >.05). However, @entity955 extended the duration of hospital stay in both groups (P <.05). CONCLUSION: Our findings indicate that @entity2399 infusion alone is not sufficient for the prophylaxis of @entity955 .

title: Intravenous @entity2399 prophylaxis for XXXX after coronary artery bypass surgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity2399 :: ('MESH:D008278', 'Chemical') :: ['magnesium sulfate']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['rhythm disorder']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation', 'Atrial fibrillation']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmia']

answer: @entity955 :: (MESH:D001281,Disease) :: ['atrial fibrillation']


abstract: BACKGROUND: Plant apoplast is the prime site for signal perception and defense response, and of great importance in responding to environmental stresses. @entity273 ( @entity274 ) plays a pivotal role in determining the responsiveness of cells to stress. However, how the apoplast proteome changes under oxidative condition is largely unknown. In this study, we initiated a comparative proteomic analysis to explore @entity274 -responsive proteins in the apoplast of @entity579 seedling roots. METHODOLOGY/PRINCIPAL FINDINGS: 14-day-old @entity579 seedlings were treated with low concentrations (300 and 600   M) of @entity274 for 6 h and the levels of relative electrolyte leakage, @entity1234 and @entity274 were assayed in roots. The modified vacuum infiltration method was used to extract apoplast proteins of @entity579 seedling roots, and then two-dimensional electrophoresis gel analysis revealed 58 differentially expressed protein spots under low @entity274 conditions. Of these, 54 were successfully identified by PMF or @entity15 / @entity15 as matches to 35 different proteins including known and novel @entity274 -responsive proteins. Almost all of these identities (98%) were indeed apoplast proteins confirmed either by previous experiments or through publicly available prediction programs. These proteins identified are involved in a variety of processes, including redox homeostasis, cell wall modification, signal transduction, cell defense and @entity1735 metabolism, indicating a complex regulative network in the apoplast of seedling roots under @entity274 stress. CONCLUSIONS/SIGNIFICANCE: The present study is the first apoplast proteome investigation of plant seedlings in response to @entity274 and may be of paramount importance for the understanding of the plant network to environmental stresses. Based on the abundant changes in these proteins, together with their putative functions, we proposed a possible protein network that provides new insights into oxidative stress response in the @entity579 root apoplast and clues for the further functional research of target proteins associated with @entity274 response.

title: Comparative proteomics analysis of the root apoplasts of XXXX seedlings in response to @entity273 .

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate']

entities_list: @entity273 :: ('MESH:D006861', 'Chemical') :: ['Hydrogen peroxide']

entities_list: @entity1234 :: ('MESH:D008315', 'Chemical') :: ['malondialdehyde']

answer: @entity579 :: (4530,Species) :: ['rice']


abstract: This study tested the hypothesis that @entity38763 , a @entity460 entry blocking drug, will improve post- @entity63 neurologic outcome when administered after a period of complete @entity2806 , and that the improvement in outcome is related to an increase in post- @entity63 cerebral blood flow (CBF). @entity2806 was produced in 31 @entity235 by temporary ligation of the aorta and venae cavae. In six @entity235 , 10 min of complete @entity2806 was followed by an infusion of @entity38763 1.0 mg X kg-1 iv over 10 min. CBF and cerebral metabolic rate for @entity26 (CMRO2) were measured pre- @entity63 , and for 90 min post- @entity63 . The results from these six @entity235 were compared with results previously obtained from eight untreated @entity235 under similar, but not identical, conditions. The CBF measured post- @entity63 in the @entity235 administered @entity38763 did not differ from the CBF measured post- @entity63 in the untreated @entity235 . Both groups showed an initial @entity450 post- @entity63 , followed by significant decreases in CBF from control values by 35 min post- @entity63 . The post- @entity63 CMRO2 also did not differ between @entity38763 treated and untreated groups. In 25 @entity235 , 11 min of complete @entity2806 was followed by an iv infusion of either @entity38763 1.0 mg X kg-1 or saline placebo. The same iv infusions were repeated at 8 and 16 h post- @entity63 . Seven @entity235 were excluded from data analysis for failure to meet pre-established protocol criteria. @entity16 was evaluated in the remaining @entity235 at 48 h post- @entity63 by an observer blinded to the treatment groups.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Effect of @entity38763 on cerebral blood flow and neurologic outcome when administered after complete @entity2806 in XXXX .

entities_list: @entity2806 :: ('MESH:D002545', 'Disease') :: ['Complete cerebral ischemia', 'cerebral ischemia']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia', 'ischemic']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['Neurologic injury']

entities_list: @entity450 :: ('MESH:D006940', 'Disease') :: ['hyperemia']

entities_list: @entity38763 :: ('MESH:D008013', 'Chemical') :: ['lidoflazine']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

answer: @entity235 :: (9615,Species) :: ['dogs']


abstract: UNASSIGNED: @entity888 ( @entity7865 ) is an addictive drug that can cause @entity137 and @entity75 . Several pieces of evidence have demonstrated that @entity7865 @entity137 results in increases in oxidative stress that regulate an intracellular signaling cascade that leads to cell death. Recently, several studies have emphasized that the overload of cytosolic @entity460 levels and mitochondrial fission into a small mitochondrial structure is involved in cell death processes. In the present study, we aimed to investigate the effects of @entity7865 @entity137 on cytosolic @entity460 overload and mitochondrial fission in @entity521 SH-SY5Y cells. Additionally, the protective effect of @entity2493 against @entity7865 -induced @entity137 was also investigated. The results of the present study demonstrated that @entity7865 significantly decreases cell viability and increases the levels of mitochondrial fission ( @entity71777 and @entity24893 ) proteins and pro-apoptotic protein, @entity589 in isolated mitochondria. The levels of @entity24893 in the cytosol of @entity7865 -treated cells had no significant differences compared to the control untreated cells. @entity7865 also significantly increased the cytosolic @entity460 levels. @entity2493 reversed the toxic effects of @entity7865 by restoring cell viability and inhibiting the increase in mitochondrial @entity71777 levels and the mitochondrial translocation of @entity24893 and @entity589 . Additionally, @entity2493 was able to reduce the @entity7865 -induced increase in cytosolic @entity460 levels and fragmented mitochondria into small globular structures in SH-SY5Y cells. The results of the present study demonstrate the potential abilities of @entity2493 to maintain the homeostasis of mitochondrial dynamics and cytosolic @entity460 levels in @entity7865 -induced @entity137 in neuronal cells.

title: @entity2493 attenuates the mitochondrial translocation of mitochondrial fission proteins and @entity589 , cytosolic @entity460 overload and cell death in @entity888 -induced @entity137 in XXXX SH-SY5Y cells.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity888 :: ('MESH:D008694', 'Chemical') :: ['Methamphetamine']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['degeneration in the brain']

entities_list: @entity2493 :: ('MESH:D008550', 'Chemical') :: ['Melatonin', 'melatonin']

entities_list: @entity521 :: ('MESH:D009447', 'Disease') :: ['neuroblastoma']

answer: @entity521 :: (MESH:D009447,Disease) :: ['neuroblastoma']


abstract: @entity6368 has been shown to produce biofilms both in experimental flow chambers and in the @entity1 host. Our laboratory has shown that extracellular DNA is an essential component of the gonococcal matrix. We have also identified a gene in @entity6368 , which we designated @entity73153 . This gene has homology with the staphylococcus-secreted thermonuclease. Our laboratory has characterized @entity73153 through phenotypic analysis of a @entity73153 deletion mutant. Biofilms grown with this strain are significantly thicker and of greater biomass than the @entity6368 1291 parent strain. Confocal microscopy indicates that the increased size of the mutant biofilms appears to be due to elevated amounts of extracellular DNA in the biofilm matrix. Chromosomal complementation of the @entity73153 mutation restored the wild-type biofilm phenotype. In addition, we have cloned and expressed the @entity73153 protein in @entity526 , and our data indicate that it has the ability to digest multiple forms of DNA and is a thermonuclease. The ability of @entity73153 to digest DNA also extends to its ability to disrupt established gonococcal biofilms through degradation of the DNA in the biofilm matrix. Our studies indicate that the @entity6368 biofilm contains DNA and that the @entity73153 protein appears to play a role in biofilm formation and remodeling.

title: The XXXX biofilm matrix contains DNA, and an endogenous nuclease controls its incorporation.

entities_list: @entity6368 :: ('485', 'Species') :: ['Neisseria gonorrhoeae', 'N. gonorrhoeae']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli']

answer: @entity6368 :: (485,Species) :: ['Neisseria gonorrhoeae']


abstract: @entity7193 peptides that induce excess slow-wave sleep have been isolated from urine and brain. A synthetic analogue to those substances, @entity7191 ( @entity7192 , @entity7191 ), was found to induce prolonged increases in slow-wave sleep and to increase electroencephalographic (EEG) delta-wave activity. @entity7192 is also pyrogenic, although this activity can be separated from its somnogenic activity. To further investigate the somnogenic actions of @entity7192 , neonatal @entity95 were used in the present study. Intraperitoneal injection of 100 micrograms/kg @entity7192 induced differential somnogenic and pyrogenic effects; from postnatal days 7-9, @entity7192 increased duration of quiet sleep (QS, the precursor of adult slow-wave sleep) and @entity25 ( @entity25 ) as judged by behavioral criteria. These animals were not febrile during the period of enhanced QS, nor did @entity7192 alter EEG delta-wave activity at this age. From postnatal days 10-15, @entity7192 induced prolonged (6 h) increases in duration of QS; both behavioral and EEG criteria were used at this age to determine duration of QS and @entity25 . Maximum @entity7192 -induced effects occurred during the 2nd h, with a parallel increase in amplitudes of EEG delta-wave activity. At this age, @entity7192 also elicited monophasic fevers and inhibition of @entity25 , with maximum effects observed during hours 3-4 postinjection. After postnatal day 16, @entity7192 -induced somnogenic and febrile responses were similar to those observed in adult @entity95 . We conclude that the mechanisms responsible for behavioral sleep states are responsive to a sleep-promoting substance early in ontogenesis.

title: Enhancement of quiet sleep in XXXX neonates by @entity7191 .

entities_list: @entity7193 :: ('CHEBI:25433', 'Chemical') :: ['Muramyl']

entities_list: @entity7191 :: ('MESH:D000119', 'Chemical') :: ['muramyl dipeptide', 'N-acetylmuramyl-L-alanyl-D-isoglutamine']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['AS', 'decreased active sleep']

answer: @entity95 :: (9986,Species) :: ['rabbit']


abstract: BACKGROUND AND OBJECTIVE: Clinical parameters such as probing depth and @entity548 on probing are commonly used for monitoring after periodontal treatment. However, these parameters have poor prognostic utility. The biomarker calprotectin is used to monitor conditions such as @entity29 because of its ability to predict disease activity. Levels of calprotectin in gingival crevicular fluid correlate with @entity2520 severity and treatment outcome. The validity of calprotectin as predictor for future @entity2520 activity has not yet been investigated. MATERIAL AND METHODS: Thirty-six subjects with generalized aggressive @entity2521 were treated with scaling and root planing (SRP), and with adjunctive antimicrobial medications. Probing depth, clinical attachment level and @entity548 on probing were assessed at baseline, and 3 and 6mo after SRP. A gingival crevicular fluid sample was collected from the initially deepest site in each @entity1 3mo after SRP and analysed for calprotectin levels. Activity was defined as a probing depth increase of >0.5mm between 3 and 6mo at the sample site. The ability of individual parameters to predict activity was analysed by construction of receiver operating characteristic curves. RESULTS: Nine active sites were identified. Clinical attachment level, probing depth, @entity548 on probing and gingival crevicular fluid volume showed no predictive utility [area under the curve (AUC) <0.6, p>0.05]. However, calprotectin concentration (AUC=0.793, p=0.01) and the total amount/sample of calprotectin (AUC=0.776, p=0.02) significantly predicted activity. @entity1 with calprotectin levels above calculated cut-off values had significantly more active sites than @entity1 with negative results. CONCLUSION: Calprotectin levels were predictors of disease activity at both site and subject levels. The calculated cut-off values provide a dichotomous basis for prospective evaluation of calprotectin as a diagnostic marker for monitoring periodontal treatment.

title: Calprotectin levels in gingival crevicular fluid predict disease activity in XXXX treated for generalized aggressive @entity2521 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity2520 :: ('MESH:D010510', 'Disease') :: ['periodontal disease']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease']

entities_list: @entity2521 :: ('MESH:D010518', 'Disease') :: ['periodontitis']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Macrophage activation--enhanced capacity to kill, in a cell that otherwise mostly scavenges--is essential for host survival from infection and contributes to containment of @entity5 . Both microbes and @entity5 cells, therefore, may be under pressure to inhibit or reverse the activation of macrophages. This reasoning led to the demonstration of macrophage deactivating factors from both microbes and @entity5 cells. In some circumstances the host itself probably requires the ability to deactivate macrophages. Macrophages are essential to the healing of wounds and repair of tissues damaged by @entity32 . Yet the cytotoxic products of the activated macrophages can damage endothelium, fibroblasts, smooth muscle and parenchymal cells (reviewed in ref. 6). Thus, after an inflammatory site has been sterilized, the impact of macrophage activation on the host might shift from benefit to detriment. These concepts led us to search for macrophage deactivating effects among polypeptide growth factors that regulate angiogenesis, fibrogenesis and other aspects of tissue repair. Among 11 such factors, two proteins that are 71% similar proved to be potent macrophage deactivators: these are @entity2533 ( @entity2533 ) and @entity6474 .

title: Deactivation of macrophages by XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours', 'tumour']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity2533 :: ('7040', 'Gene') :: ['transforming growth factor-beta 1', 'TGF-beta 1']

answer: @entity2533 :: (7040,Gene) :: ['transforming growth factor-beta']


abstract: ETHNOPHARMACOLOGICAL RELEVANCE: @entity1534 , a gram negative microaerophilic bacterium is a major etiological agent in duodenal, peptic and @entity2275 . The growing problem of antibiotic resistance by the organism demands the search for novel compounds from plant based sources. AIM OF STUDY: The present study is aimed at evaluating the antimicrobial activity of some selected medicinal plants on clinical isolates of @entity1534 circulating in Cameroon in a bid to identify potential sources of cheap starting materials for the synthesis of new drugs. MATERIALS AND METHODS: Gastric biopsy samples were obtained from @entity1 presenting with @entity532 . @entity1534 was isolated from the specimens following standard microbiology procedures. The disk diffusion method was used to determine the susceptibility of 15 isolates to ten @entity1042 plant extracts (Ageratum conyzoides, Scleria striatinux, Lycopodium cernua, Acanthus montanus, Eryngium foetidium, Aulutandria kamerunensis, Tapeinachilus ananassae, Euphorbia hirta, @entity8711 ). The minimum inhibitory concentration (MIC) and @entity6252 ( @entity6252 ) for the most active plant extracts were also determined by the agar dilution method. Results were analyzed statistically by the Fisher's exact test. RESULTS: All the plants tested demonstrated antimicrobial activity with zone diameters of inhibition ranging from 0-30mm. Of these, A. conyzoides, S. striatinux and L. cernua showed very potent antibacterial activity on the isolates. The lowest MIC and @entity6252 recorded were 0.032mg/mL and 0.098mg/mL respectively. However, the MIC of the extracts ranged from 0.032-1.0mg/mL for S. striatinux; 0.063-0.5mg/mL for L. cernua and 0.063-1.0mg/mL for A. conyzoides. The @entity6252 of the extracts ranged from 0.098-15.0mg/mL for S. striatinux; 0.098-12.5mg/mL for A. conyzoides, and 0.195-12.5mg/mL for L. cernua. The extracts had a wide spectrum of activity. The three most potent extracts possessed significant (P<0.05) inhibitory activities. CONCLUSION: The plant extracts may contain compounds with therapeutic activity.

title: In vitro anti- XXXX @entity1534 activity of extracts of selected medicinal plants from North West Cameroon.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1042 :: ('MESH:D000432', 'Chemical') :: ['methanol']

entities_list: @entity8711 :: ('MESH:D002862', 'Disease') :: ['Emilia coccinea and Scleria verrucosa']

entities_list: @entity532 :: ('MESH:D003925', 'Disease') :: ['gastroduodenal complications']

entities_list: @entity1534 :: ('210', 'Species') :: ['H. pylori', 'Helicobacter pylori']

entities_list: @entity6252 :: ('MESH:D010585', 'Disease') :: ['minimum bactericidal concentration', 'MBC']

entities_list: @entity2275 :: ('MESH:D013276', 'Disease') :: ['gastric ulcers']

answer: @entity1534 :: (210,Species) :: ['Helicobacter']


abstract: The degranulatory activity of @entity53 was tested on blood eosinophil leukocytes in vivo and in vitro. Treatment of adult ovariectomized @entity35 with 30 micrograms @entity53 /100 g body wt. increased the percentage of degranulated eosinophils from 10% to about 70% at 6 or 24 h after treatment, and increased the rate of in vitro eosinophil degranulation of those eosinophils that were non-degranulated at the time of blood sample collection. The addition of @entity53 to blood samples from untreated ovariectomized @entity35 (0.05 micrograms/ml) increased the percentage of eosinophils degranulated in vitro at 1 h of incubation from 20% to near 60%. It is suggested that @entity172 acts directly on the eosinophils, probably via specific hormone receptors. Considering the hypothesis that eosinophils are involved in the mediation of a group of responses to @entity172 in the uterus, it is proposed that the hormone-induced degranulation of these cells may have physiological implications in the regulation of the intensity and duration of the eosinophil-mediated responses. In addition, @entity172 -induced eosinophil degranulation may interfere with the action of eosinophils that have migrated to other target organs (lymphoid organs, etc.) under the action of other agents (glucocorticoid hormones, @entity112 , etc.) or conditions (immune reactions, etc.).

title: Degranulatory action of XXXX on blood eosinophil leukocytes in vivo and in vitro.

entities_list: @entity112 :: ('MESH:D006632', 'Chemical') :: ['histamine']

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen']

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol']

answer: @entity53 :: (MESH:D004958,Chemical) :: ['estradiol']


abstract: OBJECTIVES: The aim was to compare the effectiveness of intra-articular @entity3303 (IAL) versus intravenous @entity6882 and @entity3175 (IVS) in reduction of @entity2065 . DESIGN: This is a prospective randomized study. SETTING: Emergency room setting. @entity1 : Thirty-one dislocations reduced with IVS, whereas 32 @entity1 were reduced using IAL. MAIN OUTCOME MEASUREMENTS: The visual analog @entity158 scale was used before analgesic administration and during the closed manipulative reduction. Length of time since dislocation, frequency of dislocation, ease of reduction, @entity1 satisfaction, adverse effects, and duration of hospitalization were recorded. RESULTS: The IVS group had a 100% success rate, whereas the IAL group had a 19% (six of 32) failure rate (P = 0.024). However, there was no significant difference in terms of @entity158 relief (P = 0.23) or @entity1 satisfaction (P = 0.085) between both groups. In addition, @entity1 in the IAL group had a shorter duration of hospitalization and no reported complications, whereas the intravenous group had a longer hospital stay and a 29% complication rate. The cost of IAL was 32% less than the cost for IVS. CONCLUSION: IAL was more cost effective than the IVS method. IAL provided adequate @entity158 and is a viable option for analgesia during reduction of acute @entity2065 .

title: XXXX relief for reduction of @entity2065 : a prospective randomized study comparing intravenous sedation with intra-articular @entity3303 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity3175 :: ('MESH:D003975', 'Chemical') :: ['Diazepam']

entities_list: @entity3303 :: ('MESH:D008012', 'Chemical') :: ['lidocaine']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain relief and fewer complications', 'pain']

entities_list: @entity2065 :: ('MESH:D012783', 'Disease') :: ['shoulder dislocation', 'acute anterior shoulder dislocation']

answer: @entity158 :: (MESH:D010146,Disease) :: ['Pain']


abstract: @entity2522 and @entity2521 are the two main @entity2520 . Both are characterized by inflammation of the tissues surrounding the teeth but while tissue damages observed in @entity2522 are mild and reversible, destruction caused by @entity2521 is deeper and irreversible. @entity2520 and levels of degeneration of tissues surrounding teeth depend on several interacting endogenous and exogenous factors. Polymorphisms of genes encoding molecules that modulate the immune response and tissue homeostasis are the main causes of individual susceptibility to @entity2520 . The aim of this study was to investigate @entity650 , @entity688 and @entity17894 gene polymorphisms in a large number of subjects affected by either @entity2522 or @entity7278 . The sample included 750 Italian @entity1 . We found that the @entity15147 SNP located in the @entity650 gene promoter was strongly associated with the occurrence of both @entity2522 and @entity2521 . Indeed, homozygous individuals with variant allele appeared less-susceptible to both @entity2522 OR=0.47 (95% C.I. 0.27-0.82) and @entity2521 OR=0.36 (95% C.I. 0.21-0.64). No evidence of association between @entity2520 and @entity688 or @entity17894 polymorphisms was obtained. This data confirmed the role of @entity650 in susceptibility to @entity2521 among the Italian population. The evidence that @entity650 polymorphisms are also involved in @entity2522 has implications in periodontal disease pathogenesis and reduces the appeal of @entity650 as a @entity2521 biomarker.

title: XXXX GENE POLYMORPHISM MODULATES THE RISK OF PERIODONTAL DISEASES.

entities_list: @entity2520 :: ('MESH:D010510', 'Disease') :: ['Periodontal diseases', 'periodontal diseases']

entities_list: @entity7278 :: ('MESH:D055113', 'Disease') :: ['chronic periodontitis']

entities_list: @entity2522 :: ('MESH:D005891', 'Disease') :: ['gingivitis', 'Gingivitis']

entities_list: @entity2521 :: ('MESH:D010518', 'Disease') :: ['periodontitis']

answer: @entity650 :: (3569,Gene) :: ['INTERLEUKIN-6']


abstract: OBJECTIVE: To determine if clinical data and Nasal Obstruction Symptom Evaluation (NOSE) scores can be used to identify @entity1 at risk for @entity27 ( @entity27 ). DESIGN: Intake surveys using the NOSE, @entity25 ( @entity25 ), and Snore Outcomes Scale (SOS) were administered to new @entity1 visiting a facial plastic surgery practice and a rhinology practice. SETTING: An academic facial plastic surgery practice and an academic rhinology practice. @entity1 : New @entity1 to both practices. MAIN OUTCOME MEASURES: NOSE score and presence of septal deviation. RESULTS: The odds ratio (OR) for an @entity25 score higher than 10 was 2.98 (95% confidence interval [CI], 1.17-7.57) when snoring was present; 5.5 (95% CI, 1.35-22.58) when the NOSE score was 10 or higher; and 3.3 (95% CI, 0.98-11.0) when a @entity5494 was found on clinical examination. The probability of an elevated @entity25 score was 88% when all 3 factors were present and 56% when the NOSE score was not elevated. Receiver operating characteristic analysis with predictors "snore" and NOSE score of 10 or higher had an area under the curve of 0.72. With a probability cutoff of 0.5, the sensitivity was 30%, and the specificity 90%. CONCLUSIONS: Sinonasal surgery is among the most common outpatient procedures performed in the United States each year. Many @entity1 undergoing sinonasal surgery have undiagnosed @entity27 or @entity8968 , a known risk factor for @entity27 . @entity1 with @entity27 have unique perioperative needs. In @entity1 with @entity8968 , a @entity5494 , and/or snoring, there is an association between the NOSE score and the @entity25 score. The NOSE survey may serve as a simple screening instrument instead of the @entity25 for @entity1 at risk for undiagnosed @entity27 and special perioperative needs.

title: The XXXX symptom evaluation survey as a screening tool for @entity27 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity5494 :: ('MESH:D010262', 'Disease') :: ['deviated septum']

entities_list: @entity27 :: ('MESH:D020181', 'Disease') :: ['obstructive sleep apnea', 'OSA']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['Epworth Sleepiness Scale', 'ESS']

entities_list: @entity8968 :: ('MESH:D015508', 'Disease') :: ['nasal obstruction']

answer: @entity8968 :: (MESH:D015508,Disease) :: ['nasal obstruction']


abstract: BACKGROUND: A comprehensive understanding of the immune response induced by @entity2497 Bacille Calmette-Gu  rin in activation of protective T cells against @entity378 is important to develop effective therapies to combat this disease. In this study, our experiments were designed to determine effects of transforming growth factor (TGF)-beta on @entity2499 -induced T-cell activation and survival. METHODS: Fluorescence-activated cell sorter (FACS) analysis was used for detection of apo-ptotic cells by three different methods: 1). scattered light change during early phase of apoptosis; 2). detection of hypodiploid DNA, or 3). terminal deoxynucleotidyl transferase @entity1977 nick end-labeling (TUNEL) technique. Quantification of positively stained population was based on samples stained with isotype control antibodies analyzed on a FACScan. RESULTS: @entity2533 added at initiation of culture did not alter percentage of viable cells. By contrast, @entity2533 added 72 h post-activation decreased percentage of viable cells. This effect was statistically significant (p <0.05). Furthermore, addition of anti- @entity2533 MoAb together with @entity2533 abolished the ability of this cytokine to decrease survival in post-activated @entity1 T cells. Role of @entity2533 on post-activated @entity1 T cells was further confirmed by staining apoptotic nuclei with @entity2667 , which detects late events of apoptosis, and by DNA fragmentation determined using TUNEL assay. Interestingly, @entity2533 did not promote Fas-mediated killing. Finally, @entity2533 increased apoptosis of CD4(+) T cells after mycobacterial stimulation. CONCLUSIONS: This study indicated an important role for @entity2533 in suppression of protective immune response against @entity2499 by promoting elimination of post-activated T cells. Furthermore, results showed that @entity2533 had no direct effect on @entity2499 -induced up-regulation of Fas (CD95).

title: Transforming growth factor-beta decreases survival of XXXX -activated T cells.

entities_list: @entity2667 :: ('MESH:D011419', 'Chemical') :: ['propidium iodide']

entities_list: @entity378 :: ('MESH:D014376', 'Disease') :: ['tuberculosis']

entities_list: @entity2497 :: ('1765', 'Species') :: ['Mycobacterium bovis']

answer: @entity2497 :: (1765,Species) :: ['Mycobacterium bovis']


abstract: We have previously investigated the possibility of using @entity19486 as a diagnostic tool for the fluorescence detection of flat @entity150 . In these clinical studies, it was shown that following intravesical application in @entity1 , @entity19486 becomes selectively localized in transitional @entity1377 and @entity2735 ( @entity2735 ). In the present study, we characterized the biodistribution of @entity19486 in @entity35 @entity150 and normal bladder layers after intravesical administration. The biodistribution was evaluated using fluorescence microscopy with computerized image analysis to image and quantify the fluorescence of @entity19486 across the @entity5 and normal bladder wall. The results show that the photosensitizer intravesical administration route provides selective labelling of both the @entity5 and normal urothelium. A @entity19486 dose and instillation time-dependent increase in the @entity19486 fluorescence intensity in both the @entity5 and urothelium was observed, without significant @entity19486 fluorescence in the submucosa and muscle layers. The highest fluorescence ratios in @entity19486 accumulation in the @entity5 and normal urothelium to the @entity121 were achieved at 4 h with 30 micro M @entity19486 (20:1 for the urothelium to @entity121 and 30:1 for the @entity5 to @entity121 ). The difference in fluorescence intensity in @entity5 tissue to the @entity121 following instillation of 8 micro M @entity19486 was 11:1, 25:1 and 28:1 at 1, 2 and 4 h, respectively. The difference in fluorescence intensity in @entity5 tissue to the @entity121 using 30 micro M @entity19486 was 17:1, 27:1 and 31:1 at 1, 2 and 4 h, respectively. The highest absolute fluorescence levels were observed in the @entity5 at 4 h with 30 micro M @entity19486 instillation. The results suggest that under these conditions, PDT with @entity19486 is likely to produce uniform @entity5 eradication, without causing damage to the underlying muscle layers.

title: Microscopic quantification of hypercin fluorescence in an orthotopic XXXX @entity150 model after intravesical instillation.

entities_list: @entity1377 :: ('MESH:D002291', 'Disease') :: ['papillary carcinoma']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['muscle layer']

entities_list: @entity2735 :: ('MESH:D002278', 'Disease') :: ['CIS', 'carcinoma in situ']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'urothelial tumor']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder tumor', 'bladder carcinoma']

entities_list: @entity19486 :: ('MESH:C004965', 'Chemical') :: ['hypericin']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: The purpose of this trial was to evaluate the efficacy and the tolerance of high-dose therapy with autologous stem cell transplantation as part of front-line therapy in @entity978 for @entity1 with both adverse prognostic factors: high @entity5 burden at presentation and slow response to initial chemotherapy. In a prospective one-center study, 20 consecutive @entity1 with slow response ( @entity5 reduction < 75%) (16 pts) or refractory (4 pts) to 3-4 courses of conventional @entity2033 chemotherapy received high-dose therapy followed with autologous bone marrow (14 pts) or peripheral blood stem cell (6 pts) transplantation. They were 13 males, 7 females, median age 26 years (8-45). At the time of initial diagnosis, all but one of the @entity1 had B symptoms, all had high-risk @entity2033 defined as Ann Arbor stage IV (7 pts) or large mediastinal involvement (LMI = @entity5 /thorax > 0.45 at T5-T6) (6 pts) or both stage IV+LMI (7 pts). Median time between diagnosis and autotransplantation was 5 months. Intensive therapy consisted of either @entity2541 ( @entity786 1.5 g/m2 x 4, BCNU 300 mg/m2, @entity2879 200 mg/m2 x 3) (12 pts) or @entity786 120 mg/kg + 12 Gy total body irradiation for 8 @entity1 with diffuse bone or lung involvement. For pts treated with CBV, 40 Gy involved field radio-therapy was performed after hematological recovery. Median duration of @entity1398 was 16 days (9-21). Neither @entity5501 , nor @entity401 nor @entity137 death were observed. Seventeen pts are alive with no progression of the disease (16/16 in partial response after initial chemotherapy, 1/4 with refractory disease).(ABSTRACT TRUNCATED AT 250 WORDS)

title: Early intensive therapy with autotransplantation for high-risk XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity5501 :: ('MESH:D006504', 'Disease') :: ['veno-occlusive disease']

entities_list: @entity401 :: ('MESH:D017563', 'Disease') :: ['interstitial pneumonitis']

entities_list: @entity978 :: ('MESH:D006689', 'Disease') :: ["Hodgkin's disease"]

answer: @entity978 :: (MESH:D006689,Disease) :: ['Hodgkin's disease']


abstract: Danazol was given to 16 @entity1 with @entity46 in daily doses of 200 to 400mg for 4 to 6 months, and the change in serum lipids and lipoproteins was analysed. @entity1872 decreased total @entity165 by an average of 22%, @entity1674 by 56%, phospholipids by 29%, free @entity1718 by 17% and lipid @entity2627 by 42%, among which reductions in total @entity165 (p less than 0.05) and lipid @entity2627 (p less than 0.01) were statistically significant when compared with the pretreatment levels. Levels of lipids in @entity9680 and VLDL also fell: @entity9680 - @entity165 by 43%, @entity9680 - @entity1674 by 68%, @entity9680 -phospholipids by 40%, VLDL- @entity165 by 73%, VLDL- @entity1674 by 71% and VLDL-phospholipids by 48%. The decrease in @entity9680 - @entity165 (p less than 0.05), @entity9680 - @entity1674 (p less than 0.05) and @entity9680 -phospholipids (p less than 0.001) was significant. Concurrently apolipoproteins and @entity18894 activity decreased: A-I by 28% (p less than 0.001), A-II by 7% (p less than 0.05) and @entity18894 by 35%. In contrast, LDL- @entity165 increased, though slightly. Therefore, the atherogenic index defined as the ratio of LDL-c/ @entity9680 -c rose as much as 98% of the initial value. These changes seem to have arisen from impairment in the VLDL- @entity9680 cycle. The decrease in VLDL and increase in LDL indicated that VLDL was catabolised and converted to LDL at a normal rate while the formation of @entity9680 was impaired probably due to the low activity of @entity18894 and low level of apo A-I and A-II.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Effects of @entity1872 on serum lipid and lipoprotein levels in XXXX with @entity46 ].

entities_list: @entity2627 :: ('MESH:D010545', 'Chemical') :: ['peroxides']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity46 :: ('MESH:D004715', 'Disease') :: ['endometriosis']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Osteophytes of the cervical spine are usually seen in elderly adults. When prominent, they have been blamed for @entity1282 , cough, @entity7364 and dyspnoea. This paper reports on an @entity27 ( @entity27 ) @entity1 with cervical spinal @entity5040 , one cause of @entity1224 . A 75-year-old male complained of pronounced snoring. The diagnosis was mild @entity27 , apnoea hypopnoea index was 9.4. @entity1 reported no restrictions in neck movements, experiences of neck @entity4048 . Previously, @entity1 underwent a tonsillectomy due to discomfort in the pharyngeal region. A lateral cephalometric image was taken to observe airway before oral appliance therapy. The image revealed the presence of large @entity5040 or @entity627 , lying on anterior surfaces from the fourth to seventh cervical vertebrae. A computed tomography (CT) image revealed the relationship of airway position to the spine. In the reconstructed three-dimensional (3D) image, the airway appeared displaced to the right of the craniomandiblar bone, with the hyoid bone similarly displaced in a manner to that of the airway. The spine also appeared displaced to the left side ofcraniomandiblar bone. Additionally, the 3D image revealed calcification of the stylohyoideum ligament and ligamentum nuchae. This present case highlights the necessity of CT examination for @entity27 @entity1 . There were several ligament calcifications in the head and neck region. Cervical spine @entity5040 , as a component of @entity5039 , have been associated with @entity1282 and @entity7364 . It was reported that bilateral @entity3746 was caused by @entity5040 compressing the post-cricoid area of larynx.

title: A case of @entity27 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient']

entities_list: @entity627 :: ('MESH:D012216', 'Disease') :: ['sclerotic enthesopathy']

entities_list: @entity5040 :: ('MESH:D054850', 'Disease') :: ['osteophytes']

entities_list: @entity27 :: ('MESH:D020181', 'Disease') :: ['obstructive sleep apnoea', 'OSA']

entities_list: @entity5039 :: ('MESH:D004057', 'Disease') :: ["Forestier's or cervical spine disease"]

entities_list: @entity7364 :: ('MESH:D055154', 'Disease') :: ['dysphonia']

entities_list: @entity4048 :: ('MESH:D019547', 'Disease') :: ['pain or neck trauma']

entities_list: @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia']

entities_list: @entity3746 :: ('MESH:D014826', 'Disease') :: ['vocal cord paralysis']

entities_list: @entity1224 :: ('MESH:D000402', 'Disease') :: ['airway obstruction']

answer: @entity4048 :: (MESH:D019547,Disease) :: ['anterior cervical osteophytes']


abstract: AIMS: Left atrial (LA) function helps to preserve @entity998 and to control pulmonary capillary wedge pressure in the setting of left ventricular (LV) impairment, but little is known about the contribution of the LA function to @entity943 . We sought whether LA booster pump function was associated with @entity943 in @entity1 undergoing primary prevention @entity737 ( @entity737 ) implantation for @entity384 ( @entity384 ), independent of @entity6475 ( @entity6475 ) and @entity1480 ( @entity1480 ). METHODS AND RESULTS: We identified 124 @entity384 @entity1 (56    13, 67 male) who underwent echocardiography pre- @entity737 implantation for primary prevention. The main outcome measure was appropriate @entity737 therapy (anti- @entity591 pacing or shock). The mitral A-wave was used as an LA functional marker. @entity1480 was defined as standard deviation of time to peak strain of each segment. Over a median follow-up of 3.8    2.2 years, 36 @entity1 had appropriate @entity737 therapy, including 23 shocks. @entity1 with appropriate @entity737 therapy had lower A-wave velocity (P < 0.001), larger LA volume (P < 0.001), and impaired circumferential @entity1480 (P = 0.006), but similar ejection fraction (EF) (P = 0.40) and @entity6475 (P = 0.11). In sequential Cox proportional hazards models, A-wave, E/A ratio, and @entity6475 were significantly associated with outcomes, independent of age, sex, and @entity299 or @entity714 . In nested Cox models, mitral A-wave had a prognostic value @entity1002 (E/A, E/e', and LA volume) and @entity1480 . CONCLUSION: LA booster pump function was an independent and incremental predictor of @entity943 in @entity384 over @entity6475 and @entity1480 , and may aid better risk stratification in this population.

title: Left atrial booster pump function is an independent predictor of subsequent life-threatening XXXX in non-ischaemic cardiomyopathy.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity998 :: ('MESH:D002303', 'Disease') :: ['cardiac output']

entities_list: @entity714 :: ('MESH:D002037', 'Disease') :: ['left bundle branch block']

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['NICM', 'non-ischaemic dilated cardiomyopathy']

entities_list: @entity737 :: ('MESH:D057873', 'Disease') :: ['ICD', 'implantable cardioverter-defibrillator']

entities_list: @entity6475 :: ('MESH:D013180', 'Disease') :: ['global longitudinal strain', 'GLS']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['tachycardia']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac resynchronization therapy defibrillator']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['ventricular arrhythmia', 'arrhythmias']

entities_list: @entity1002 :: ('MESH:D018487', 'Disease') :: ['incremental to models with LV systolic (EF and GLS) and diastolic functional parameters']

entities_list: @entity1480 :: ('MESH:C563184', 'Disease') :: ['MD', 'mechanical dispersion']

answer: @entity943 :: (MESH:D001145,Disease) :: ['ventricular arrhythmias']


abstract: UNASSIGNED: Cyclical intravenous @entity5520 therapy is widely used to treat @entity1 with @entity6926 ( @entity6926 ), but little is known about long-term treatment outcomes. We therefore reviewed 37 @entity1 with @entity6926 ( @entity6926 type I, n   =   1; @entity6926 type III, n   =   14; and @entity6926 type IV, n   =   22) who started intravenous @entity5520 therapy before 5 years of age (median 2.2 years; range, 0.1 to 4.8 years), and who had a subsequent follow-up period of at least 10 years (median 14.8 years; range, 10.7 to 18.2 years), during which they had received intravenous @entity5520 treatment ( @entity5279 or @entity4381 ) for at least 6 years. During the observation period, the mean lumbar spine areal bone mineral density Z-score increased from -6.6 (SD 3.1) to -3.0 (SD 1.8), and weight Z-score increased from -2.3 (SD 1.5) to -1.7 (SD 1.7) (p   <   0.001 and p   =   0.008). At the time of the last assessment, @entity1 with @entity6926 type IV had significantly higher height Z-scores than a control group of @entity1 matched for age, gender, and @entity6926 type who had not received @entity171 . @entity1 had a median of six femur @entity174 (range, 0 to 18) and five tibia @entity174 (range, 0 to 17) during the follow-up period. At baseline, 35% of vertebra were affected by @entity3814 , whereas only 6% of vertebra appeared compressed at the last evaluation (p   <   0.001), indicating vertebral reshaping during growth. Spinal fusion surgery was performed in 16 @entity1 (43%). Among the 21 @entity1 who did not have spinal fusion surgery, 13 had @entity1635 with a curvature ranging from 10 to 56 degrees. In conclusion, long-term intravenous @entity5520 therapy was associated with higher Z-scores for lumbar spine areal bone mineral density and vertebral reshaping, but long-bone @entity174 rates were still high and the majority of @entity1 developed @entity1635 .    2015 American Society for Bone and Mineral Research.

title: Intravenous @entity5520 Therapy of Young XXXX With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients']

entities_list: @entity5279 :: ('MESH:C019248', 'Chemical') :: ['pamidronate']

entities_list: @entity171 :: ('MESH:D004164', 'Chemical') :: ['bisphosphonates']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'fracture']

entities_list: @entity3814 :: ('MESH:D050815', 'Disease') :: ['compression fractures']

entities_list: @entity1635 :: ('MESH:D012600', 'Disease') :: ['scoliosis']

entities_list: @entity5520 :: ('D004164', 'Chemical') :: ['bisphosphonate']

entities_list: @entity4381 :: ('MESH:C088658', 'Chemical') :: ['zoledronic acid']

entities_list: @entity6926 :: ('MESH:D010013', 'Disease') :: ['osteogenesis imperfecta', 'OI']

answer: @entity1 :: (9606,Species) :: ['Children']


abstract: OBJECTIVE: To assess clinical features of therapeutic efficacy and tolerability of @entity15177 (saphris) in stopping acute @entity716 attacks in @entity1 with @entity1032 and to determine spectrum of action of this drug. MATERIAL AND METHODS: We examined 30 female inpatients with acute hallucinatory/delusive and @entity162 /delusive states in attack-like @entity161 and @entity716 . Treatment was conducted according to standard schedule during 42 days. Saphris was used in sublingual tablets in daily dose 20 mg (10 mg in morning and 10 mg at night). Clinical/psychopathological and psychometric methods were applied. RESULTS: To the end of the study, the positive effect was achieved in 86.6% of the @entity1 with >= 30% reduction in PANSS scores. Good (reduction by 50-60%) and marked (reduction by >= 70%) effects were identified in 33.3% and 23.3% @entity1 , respectively. To the 42nd day, the reduction in the severity of disorders was 57.3% on average in the whole group, 54.1% in the subgroup of hallucinatory/delusive @entity716 and 62.1% in the @entity1 with @entity162 /delusive states. Distinct sedative, antimania, antipsychotic and antiparaphrenia components were detected in the spectrum of psychotropic action of saphris. Adverse effects were observed in 76.7% of the @entity1 with predominance of neurological symptoms (39.9%) and mental side-effects (34.0%). Somatic/autonomic (20.7%) and other side-effects (5.4%) were less frequent. Mild side-effects (71.2%) were most frequent in the structure of the severity. CONCLUSION: According to the results of therapeutic efficacy and tolerability of saphris as well as the high compliance of @entity1 , recommendations for using this medication in psychiatric practice were developed.

title: [Clinical experience and perspectives of using XXXX in stopping acute endogenous @entity716 ].

entities_list: @entity15177 :: ('MESH:C522667', 'Chemical') :: ['asenapine']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1032 :: ('MESH:D008607', 'Disease') :: ['endogenous mental diseases']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia']

entities_list: @entity716 :: ('MESH:D011605', 'Disease') :: ['psychotic', 'endogenous affective psychosis', 'psychosis']

answer: @entity15177 :: (MESH:C522667,Chemical) :: ['asenapine']


abstract: Fifty-eight @entity1 conservatively treated for T1 @entity0 are analyzed for cosmetic outcome; 17 had concomitant adjuvant combination chemotherapy ( @entity786 , @entity632 , 5 @entity1487 ). The results are evaluated by clinical criteria and a quantitative measurement by use of light field projection at 33 months median follow-up. Surgery consisted of lumpectomy and axillary dissection; radiotherapy was given to the breast only except for additional internal mammary irradiation in central and medial lesions. (50 Gy whole breast, 64 Gy electron/photon boost). Questionnaires are used for inquiry on @entity1 experience: 88% of the @entity1 experienced a good to excellent cosmetic outcome. According to the panel only 64% show a good to excellent cosmesis. Panel-scores on asymmetry are compared with quantitative measurements. More @entity2910 and probably a higher degree of @entity82 in the boost area is found in the chemotherapy group. No differences in cosmetic outcome, complication rates, and @entity1 experiences are seen. Results are compared with published data.

title: Conservative XXXX treatment: analysis of cosmetic results and the role of concomitant adjuvant chemotherapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['adriamycin']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancers']

entities_list: @entity2910 :: ('MESH:D004941', 'Disease') :: ['esophagitis']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity1487 :: ('MESH:D005472', 'Chemical') :: ['fluorouracil']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: This experimental trial was devised to assess whether selective beta3-adrenergic receptor (AR) stimulation and simultaneous blockade of alpha2-AR would affect thermoregulation. With this purpose, the individual and combined administration of a beta-AR agonist, @entity47322 , and an alpha2-AR antagonist, @entity3160 , were evaluated. @entity3160 produced a marked decrease (p < 0.001) in body temperature one hour after administration (5 mg kg(-1), i.p.) and blocked the thermogenic effect of @entity47322 (1 mg kg(-1), i.p.) when simultaneously administered. Uncoupling protein-2 expression in skeletal muscle was downregulated (p < 0.05) by @entity47322 , while @entity3160 had no effect. White adipose tissue @entity5484 and muscle @entity5485 were not modified by either @entity47322 or @entity3160 administration. Liver @entity5484 mRNA expression was significantly decreased by @entity3160 (p < 0.05). However, this downregulation does not seem to explain the reduction in temperature produced by @entity3160 given the fact that @entity47322 produced a similar downregulation of hepatic @entity5484 (p < 0.05). The present work indicates that alpha2-AR antagonism blocks the thermogenic effects mediated by beta3-AR stimulation, contrary to our expectations, suggesting a possible interplay between both mechanisms. Moreover, these effects are not apparently explained by changes in @entity5484 and @entity5485 .

title: Interactions between an alpha2-adrenergic antagonist and a beta3-adrenergic agonist on the expression of XXXX and @entity5485 in rats.

entities_list: @entity3160 :: ('MESH:D015016', 'Chemical') :: ['yohimbine', 'Yohimbine']

entities_list: @entity47322 :: ('MESH:C101319', 'Chemical') :: ['trecadrine']

answer: @entity5484 :: (54315(Tax:10116),Gene) :: ['UCP2']


abstract: UNASSIGNED: A variety of imaging, neuropsychological, and genetic biomarkers have been suggested as potential biomarkers for the identification of @entity73 ( @entity73 ) in @entity1 who later develop @entity195 ( @entity195 ). Here, we systematically evaluated the most promising combinations of these biomarkers regarding discrimination between stable and converter @entity73 and reflection of disease staging. @entity195 Neuroimaging Initiative data of @entity195 (n=144), controls (n=112), stable (n=265) and converter (n=177) @entity73 , for which @entity2204 status, neuropsychological evaluation, and structural, @entity413 , and amyloid imaging were available, were included in this study. @entity4024  ve Bayes classifiers were built on @entity195 and controls data for all possible combinations of these biomarkers, with and without stratification by amyloid status. All classifiers were then applied to the @entity73 cohorts. We obtained an accuracy of 76% for discrimination between converter and stable @entity73 with @entity413 positron emission tomography as a single biomarker. This accuracy increased to about 87% when including further imaging modalities and genetic information. We also identified several biomarker combinations as strong predictors of time to conversion. Use of amyloid validated training data resulted in increased sensitivities and decreased specificities for differentiation between stable and converter @entity73 when amyloid was included as a biomarker but not for other classifier combinations. Our results indicate that fully independent classifiers built only on @entity195 and controls data and combining imaging, genetic, and/or neuropsychological biomarkers can more reliably discriminate between stable and converter @entity73 than single modality classifiers. Several biomarker combinations are identified as strongly predictive for the time to conversion to @entity195 .

title: Accurate Prediction of Conversion to XXXX using Imaging, Genetic, and Neuropsychological Biomarkers.

entities_list: @entity2204 :: ('348', 'Gene') :: ['apolipoprotein E']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['MCI', 'mild cognitive impairment']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', "Alzheimer's disease", "Alzheimer's Disease"]

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity195 :: (MESH:D000544,Disease) :: ['Alzheimer's Disease']


abstract: Fifty-three @entity1 with @entity4941 ( @entity4941 ) were seen during the acute stage of the disease. HLA-Bw 35 was positive in 33 out of 39 tested @entity1 . At first presentation, all examined @entity1 (N = 23) had ultrasound abnormalities (generalized hypodensity, single or multiple hypodense areas). Serum T4 and/or T3 were increased in 24/52, free T4 in 11/23, and the TSH response to @entity1218 was flat in 8/11 @entity1 . Six of 12 in whom volumetry was performed had goitres. Thirty-seven @entity1 were re-examined after a mean follow-up interval of 46.5 months. At this follow-up, serum T4, free T4 and T3 levels as well as the sonographically determined thyroid volume had decreased, but there was still abnormalities by ultrasound detected in 14/36 @entity1 ; 19.4% had focal sonolucent lesions, whereas the prevalence of such lesions was only 3.1% in asymptomatic controls. Three @entity1 were @entity1375 at the follow-up, whereas all others were euthyroid. @entity1 with abnormal ultrasound findings were of the same age and had a similar thyroid size, but a slightly higher TSH and a significantly (P less than 0.02) lower free T4 than those with normal ultrasound findings. They also had a higher prevalence of thyroid autoantibodies in low titres. Serum thyroglobulin was elevated in more than half of the @entity1 during the acute phase, but only in 1 out of 11 @entity1 during follow-up. Thyroglobulin at the follow-up was not related to TSH, but there was a correlation with thyroid volume (r = 0.57).(ABSTRACT TRUNCATED AT 250 WORDS)

title: The sonographical and functional sequelae of de Quervain's XXXX : long-term follow-up.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1375 :: ('MESH:D007037', 'Disease') :: ['subclinically hypothyroid']

entities_list: @entity4941 :: ('MESH:D013968', 'Disease') :: ['subacute thyroiditis', 'SAT']

answer: @entity4941 :: (MESH:D013968,Disease) :: ['subacute thyroiditis']


abstract: BACKGROUND: Morbus Morbihan is a rare complication of @entity6509 , consisting of a persistent lymphoedema of the upper part of the face. It has typically a chronic course, unspecific histopathological findings and an extreme refractoriness to therapy. @entity1 AND METHODS: Between February 2008 and January 2010, 5 @entity1 with Morbus Morbihan were observed at the Department of Ophthalmology of the University Medical Centre Mainz. In the present cohort study, we describe the clinical, laboratory and histological findings that led to the diagnosis. The course of the affection and the results of different therapeutic options are also reported. RESULTS: Each @entity1 underwent a complete ophthalmological examination, as well as general and dermatological consultations. All @entity1 showed facial skin alterations typical for @entity6509 . 4 out of 5 subjects underwent a lid biopsy to confirm the diagnosis of Morbus Morbihan, one @entity1 refused it. Initial treatment consisted of various systemic and local medical therapies, however, with poor success. One @entity1 had intravenous therapy with @entity288 elsewhere with no effect. We treated 3 cases with intralesional @entity2713 injections with good results. 2 @entity1 underwent upper lid blepharoplasty. Results of surgery remained stable also due to manual lymph drainage and intralesional injections of triamcinolon. No complications or side effects were seen in @entity1 treated with @entity2713 . CONCLUSIONS: Morbus Morbihan can be diagnosed only after excluding other conditions leading to chronic lid swelling. In our series, good results were achieved with intralesional injection of @entity2713 . Surgery also led to relevant improvements for a long period (13 months), with some adjuvant therapy. The treatment of chronic eyelid @entity4 associated with @entity6509 remains a challenge for the ophthalmologist and the oculoplastic surgeon.

title: [ @entity4 and XXXX (Morbus Morbihan): diagnostic and therapeutic challenges].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['oedema']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

entities_list: @entity2713 :: ('MESH:D014221', 'Chemical') :: ['triamcinolone']

answer: @entity6509 :: (MESH:D012393,Disease) :: ['rosacea']


abstract: In Germany, the incidence of @entity7135 is approximately 1/100,000 and has not risen during recent years. Transmission occurs by direct contact with respiratory droplets, mostly from asymptomatic carriers and less frequently from @entity1 with @entity66 . The incubation period can vary from 2-10 days but usually is 3-4 days. Incidence is highest in @entity1 and decreases with age. The mortality from @entity7135 is approximately 10%. In case @entity10217 is clinically suspected antibiotic treatment (in Germany with @entity3397 or a cephalosporin) should not be delayed. @entity1 must be isolated for at least 24 hours after the institution of antibiotic therapy. For early detection of local outbreaks, public health authorities should be quickly informed of suspected cases. @entity1 in close contact should be treated with antimicrobial chemoprophylaxis. In addition to @entity1215 , @entity2177 or @entity2756 can be used for chemoprophylaxis. For control of local outbreaks of serogroup C @entity7135 , the meningococcal vaccine can be used.

title: [Prevention of XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['Persons', 'children', 'Patients', 'patients']

entities_list: @entity2756 :: ('MESH:D002443', 'Chemical') :: ['ceftriaxone']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['meningococal disease']

entities_list: @entity10217 :: ('MESH:D008585', 'Disease') :: ['meningococcal meningitis']

entities_list: @entity2177 :: ('MESH:D002939', 'Chemical') :: ['ciprofloxacin']

entities_list: @entity3397 :: ('MESH:D010400', 'Chemical') :: ['penicillin G']

entities_list: @entity1215 :: ('MESH:D012293', 'Chemical') :: ['rifampin']

entities_list: @entity7135 :: ('MESH:D008589', 'Disease') :: ['meningococcal disease']

answer: @entity10217 :: (MESH:D008585,Disease) :: ['meningococcal meningitis']


abstract: BACKGROUND: Intranasal corticosteroids are effective for the treatment of @entity2023 . Sensory attributes associated with these sprays may affect @entity1 preference and adherence to treatment regimens. OBJECTIVES: These 2 studies compared @entity1 ' perceptions of and preferences for specific sensory attributes of @entity4184 aqueous nasal spray (BANS) and @entity5023 nasal spray (FPNS). METHODS: In 2 multicenter, randomized, single-blind ( @entity1 ), single-dose, 2-period, 1-day crossover studies, adults with mild to moderate @entity2023 received single doses of BANS (one 32-pg spray per nostril in both studies, 64-microg total dose) and FPNS (two 50-microg sprays per nostril in study 1, 200-pg total dose; one 50-microg spray per nostril in study 2, 100-microg total dose). Study 1 compared the once-daily recommended starting doses of BANS and FPNS, and study 2 compared BANS with half the once-daily recommended dose of FPNS to balance the number of actuations for delivery of study drug. @entity1 completed the 23-item Sensory Perceptions Questionnaire and indicated their product preference (if any). RESULTS: A total of 110 @entity1 and 71 @entity1 in study 1 and 136 @entity1 and 54 @entity1 in study 2 were randomized to treatment. None had previously used BANS or FPNS. In both studies, fewer @entity1 perceived scent or taste (both P < 0.001 in both studies), forceful spray (P < 0.001 in both studies), and a wet feel in both the nose and throat (study 1, P < 0.004; study 2, P < 0.002) with BANS than with FPNS. In addition, more @entity1 in both studies liked the spray force (study 1, P < 0.01; study 2, P < 0.001) and moisture content in the throat (study 1, P < 0.001; study 2, P < 0.006) of BANS and indicated a greater overall satisfaction with the sensory features of BANS than those of FPNS (study 1, P < 0.001; study 2, P < 0.015). In analyses that included all responding @entity1 , 54.4% of @entity1 in study 1 preferred BANS and 37.8% preferred FPNS (P < 0.022). In study 2, 47.4% preferred BANS and 41.1% preferred FPNS (not significant). Of the 92.2% of @entity1 in study 1 and 88.4% in study 2 who specified a product preference, 59.0% preferred BANS and 41.0% preferred FPNS in study 1 (P = 0.021), and 53.6% preferred BANS and 46.4% preferred FPNS in study 2 (not significant). CONCLUSIONS: On the basis of perceptions of specific sensory attributes reported after 1 administration in these 2 studies, BANS was rated as more pleasing and preferred over the recommended QD starting dose of FPNS, and was also rated as more pleasing than half the QD recommended starting dose of FPNS.

title: Two multicenter, randomized, single-blind, single-dose, crossover studies of specific sensory attributes of @entity4184 aqueous nasal spray and XXXX nasal spray.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'patient', 'men']

entities_list: @entity4184 :: ('MESH:D019819', 'Chemical') :: ['budesonide']

entities_list: @entity5023 :: ('MESH:C065382', 'Chemical') :: ['fluticasone propionate']

entities_list: @entity2023 :: ('MESH:D006255', 'Disease') :: ['allergic rhinitis']

answer: @entity5023 :: (MESH:C065382,Chemical) :: ['fluticasone propionate']


abstract: BACKGROUND: @entity1 seek @entity1058 ( @entity1058 ) treatments for a variety of @entity1576 , e.g., @entity565 and @entity1729 ( @entity1729 ). No previous studies have reviewed the data available in medical records from Australian clinics. This study aims to identify the characteristics of @entity1 with @entity1576 who visited a @entity1058 teaching clinic at RMIT University in Melbourne, Australia. METHODS: Primary data from January 2010 to December 2011 were collected from @entity1 records in a @entity1058 teaching clinic at RMIT University. @entity1 data, including demographics, primary complaint, clinical history, lifestyle, @entity1058 treatment, and adverse events, were analyzed with descriptive statistics and the Chi square test using SPSS version 21.0. RESULTS: From 1677 clinical records we identified 261 @entity1 with @entity1576 . The @entity1 made a total of 842 visits (mean: 3.2 visits/ @entity1 ; range: 1-34 visits) during the study period. The mean age of the @entity1 was 38.5      17.9  years, and the majority were female (65.5  %). The most common @entity1576 were @entity1729 (27.8  %), cough (20.8  %), @entity2023 or @entity2023 (18.6  %), sinus congestion (11.2  %), and @entity565 (7.6  %). Acupuncture was given at almost all visits (97.5  %) and was frequently combined with herbs (64.0  %). Fifteen adverse events were reported, but none were considered severe. CONCLUSION: In the @entity1058 teaching clinic, respiratory conditions were a common presenting complaint of @entity1 , and were safely treated with a combination of acupuncture and herbs.

title: Management of @entity1576 in a XXXX teaching clinic in Australia: review of clinical records.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient', 'People']

entities_list: @entity2023 :: ('MESH:D006255', 'Disease') :: ['hay fever', 'allergic rhinitis']

entities_list: @entity1729 :: ('MESH:D012141', 'Disease') :: ['URTI', 'upper respiratory tract infection']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory disorders']

entities_list: @entity1058 :: ('MESH:C562377', 'Disease') :: ['Chinese medicine', 'CM']

answer: @entity1058 :: (MESH:C562377,Disease) :: ['Chinese medicine']


abstract: BACKGROUND: Pulsed-wave Doppler determination of the pulmonary artery acceleration time (PAAT) as a surrogate for pulmonary artery pressure was found to be of clinical value for assessment of @entity120 ( @entity120 ) with studies to date exclusively performed in adults. This study aims to provide representative, normal reference values for PAAT in @entity1 of all ages. Moreover, we validated abnormal PAAT values in 54 @entity1 with @entity120 . METHODS AND RESULTS: We conducted a prospective echocardiographic study in 756 healthy @entity1 (aged 1 day to 18 years) and in 54 @entity1 with @entity120 . Possible associations of age, body length, body weight, body surface area, and heart rate on PAAT were investigated. The PAAT correlated positively with age (r=0.848), body length (r=0.871), body surface area (r=0.856), and body weight (r=0.825) and negatively with heart rate (r=-0.906). PAAT increased with age (neonates: median: 81 ms, range: 53-104; 18th year of life: median: 151 ms, range: 107-187). Receiver operating characteristic analysis for detecting @entity120 @entity1 using age-specific z scores showed an excellent performance of PAAT (P<0.001; area under the curve, 0.98; 95% confidence interval, 0.97-0.99) with a best cutoff score according to Youden index of -1.565 (sensitivity: 92%, specificity: 96%). PAAT values of @entity120 @entity1 negatively correlated (  =-0.497) with pulmonary vascular resistance. CONCLUSIONS: The PAAT normal reference values and z scores we provide here will be useful to identify @entity1 with a shortened PAAT. Abnormal PAAT values with scores <-2 were predictive of @entity120 .

title: Normal Reference Values and z Scores of the Pulmonary Artery Acceleration Time in XXXX and Its Importance for the Assessment of Pulmonary Hypertension.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'children']

entities_list: @entity120 :: ('MESH:D006976', 'Disease') :: ['pulmonary hypertension', 'PH']

answer: @entity1 :: (9606,Species) :: ['Children']


abstract: BACKGROUND: While intraoperative neurophysiological monitoring (IOM) for @entity5 has become a standard in neurosurgical practice, IOM for intradural extramedullary @entity5 (IDEMs) is still under debate. The aim of this study is to evaluate the role of IOM during surgery for IDEMs. METHODS: From March 2008 to March 2013, 68 @entity1 had microsurgery with IOM for IDEMs (31 @entity808 , 25 @entity1653 , 6 @entity424 of the cauda/filum terminalis, 4 @entity8 ). The IOM included somatosensory evoked potentials (SEPs), motor evoked potentials (MEPs), and - in selected cases - D-waves. Also preoperative and postoperative neurophysiological assessment was performed with SEPs and MEPs. All @entity1 were evaluated at admission and at follow up (minimum 6 months) with the Modified McCormick Scale (mMCs). RESULTS: Three different IOM patterns were observed during surgery: no change in evoked potentials (63 cases), transitory evoked potentials change (3 cases) and loss of evoked potentials (2 cases). In the first setting surgery was never stopped and a @entity5 removal was achieved (no stop surgery group). In 3 cases of transitory evoked potentials change, surgery was temporarily halted but the @entity5 were at the end completely removed (stop and go surgery group). In 2 more @entity1 the loss of evoked potentials led to an incomplete resection (stop surgery group). No @entity1 presented a worsening of the pre-operative clinical conditions (at admission 47 @entity1 presented mMCs 1-2 and 21 @entity1 mMCs 3-5, while at follow up 62 @entity1 are mMCS 1-2 and 6 @entity1 mMCs 3-5). CONCLUSIONS: In our series significant IOM changes occurred in 5 out of 68 @entity1 with IDEMs (7.35%), and it is conceivable that the modification of the surgical strategy - induced by IOM - prevented or mitigated @entity16 in these cases. Vice versa, in 63 @entity1 (92.65%) IOM invariably predicted a good neurological outcome. Furthermore this technique allowed a @entity5 removal in IDEMs placed in difficult locations as @entity3161 or in antero/antero-lateral position (where rotation of spinal cord can be monitored) and even in case of @entity5 adherent to the spinal cord without a clear cleavage plane.

title: Intraoperative neurophysiological monitoring for intradural extramedullary XXXX : Why not?

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity808 :: ('MESH:D009442', 'Disease') :: ['schwannomas']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['dermoid cysts and 2 other lesions']

entities_list: @entity424 :: ('MESH:D004806', 'Disease') :: ['ependymomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'safer tumor', 'radical tumor', 'intramedullary tumors', 'tumors']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological injury']

entities_list: @entity1653 :: ('MESH:D008579', 'Disease') :: ['meningiomas']

entities_list: @entity3161 :: ('MESH:D020511', 'Disease') :: ['cranio-vertebral junction']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumors']


abstract: @entity3288 , a Gram-negative obligate anaerobic black-pigmented oral bacterium, belongs to a small group of microorganisms that is closely associated with the @entity2520 . Lipopolysaccharide (LPS), an outer membrane component, is one of the main virulence factors of this bacterium. The aim of this study was to examine the effects of Prev. intermedia lipopolysaccharide, extracted by the hot- @entity3971 -water method, on differentiation (alkaline phosphatase activity) and mineralisation ( @entity460 incorporation) of fetal @entity19 calvarial cells in vitro and to determine the release of the important osteolytic factors @entity842 , @entity777 ( @entity777 ) and matrix metalloproteinases by these cells after treatment with different concentrations of Prev. intermedia lipopolysaccharide (0.2-25 microg/ml). By gelatin zymography, we also characterized the matrix metalloproteinases released by these osteoblasts. Treatment with Prev. intermedia lipopolysaccharide dose-dependently inhibited bone formation by reducing alkaline phosphatase activity and @entity460 incorporation and induced the release of @entity842 , @entity777 and the latent proforms of @entity5780 and @entity1235 by fetal @entity19 osteoblasts in organoid culture. These results indicate that the lipopolysaccharide from Prev. intermedia not only participates in periodontal tissue destruction and alveolar bone resorption, but also inhibits bone formation.

title: Effects of lipopolysaccharide extracted from @entity3288 on bone formation and on the release of osteolytic mediators by fetal XXXX osteoblasts in vitro.

entities_list: @entity2520 :: ('MESH:D010510', 'Disease') :: ['initiation of periodontal diseases']

entities_list: @entity3288 :: ('28131', 'Species') :: ['Prevotella intermedia']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

answer: @entity19 :: (10090,Species) :: ['mouse']


abstract: This is a retrospective analysis of 188 @entity1 who underwent @entity348 ( @entity348 ) in one or two fractions before bone marrow transplantation (BMT) for a @entity1503 . While 139 @entity1 had eye shielding during @entity348 to decrease @entity231 formation, 49 did not. The blocks used for shielding caused cylindrical areas of decreased dose intensity in the brain. The aim of the study was to determine if there was an increased risk of @entity735 or in the CNS after shielding of the eyes. The probability and severity of @entity231 formation with and without shielding were also evaluated. None of the 49 @entity1 without shielding had a relapse in their eyes or in the CNS after BMT. Of the @entity1 with shielding, none had a @entity735 but two of the 139 (1.4%) had a CNS relapse. The incidence of @entity231 without shielding was 90% (19 of 21 evaluable @entity1 ), while with shielding it was 31% (20 of 64). Severe @entity231 were present in eight of 21 (38%) @entity1 without and two of 64 (3%) @entity1 with shielding. The probability of staying @entity231 free for at least five years was 0.77 with and 0.33 without shielding, at 8 years it was 0.53 and 0.24 respectively. The relative risk of developing a @entity231 without shielding vs shielding was three (95% CI=1.5; 5.9). It appears that the incidence of @entity735 and CNS is not increased when the eyes are shielded during @entity348 . Shielding increased the latency time of @entity231 formation and decreased the severity of @entity231 .

title: Eye shielding during @entity348 for bone marrow transplantation in XXXX transplanted for a @entity1503 : risks and benefits.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity231 :: ('MESH:D002386', 'Disease') :: ['cataracts', 'cataract']

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematological disorder']

entities_list: @entity735 :: ('MESH:D005124', 'Disease') :: ['relapse in the eyes']

entities_list: @entity348 :: ('MESH:C535338', 'Disease') :: ['TBI', 'total body irradiation']

answer: @entity1 :: (9606,Species) :: ['children']


abstract: OBJECTIVES: @entity1209 ( @entity1209 ) is the most common complication seen following laparoscopic surgery. Our study sought to evaluate the efficacy of the newer drug @entity7274 with that of @entity3974 , in combination with @entity619 , for @entity1209 in @entity1 undergoing laparoscopic hysterectomies.   . METHODS: A total of 90 @entity1 , aged between 30-50 years old, posted for elective laparoscopic hysterectomies under general anesthesia belonging to the American Society of Anesthesiologist (ASA) physical status I and II were included in the study. @entity1 were randomly divided into one of two groups (n=45). Before induction, @entity1 in the first group (group I) received 0.075mg @entity7274 with 8mg @entity619 and @entity1 in the second group (group II) received 4mg @entity3974 with 8mg @entity619 . Postoperatively, any incidences of @entity391 , requirement of rescue antiemetic, and side effects were recorded. @entity1 's hemodynamics were also monitored. Statistical analysis was done using Student's t-test, chi-square test, and Fisher's exact test.   . RESULTS: Preoperative, intraoperative, and postoperative heart rate, mean arterial pressure, peripheral capillary @entity26 saturation were statistically not significant (p>0.050) in either group. In group II, eight @entity1 had @entity390 in the first two hours and three @entity1 had @entity390 in the two to six-hour postoperative period. In group I, three @entity1 experienced @entity390 in the first six hours period. Eight @entity1 in group II had vomited in the first two-hour period compared to one @entity1 in group I (p=0.013). The requirement of rescue antiemetic was greater in group II than group I (20% vs. 4%). No side effects of antiemetic use were observed in either group.   . CONCLUSION: The combination of @entity7274 with @entity619 is more effective in treating early, delayed, and long term @entity1209 compared to @entity3974 with @entity619 in @entity1 undergoing elective laparoscopic hysterectomies under general anesthesia.

title: @entity1209 and Vomiting: @entity7274 with XXXX vs. @entity3974 with @entity619 in Laparoscopic Hysterectomies.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'Patient']

entities_list: @entity3974 :: ('MESH:D017294', 'Chemical') :: ['ondansetron']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['early or delayed vomiting']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity7274 :: ('MESH:C083418', 'Chemical') :: ['palonosetron']

entities_list: @entity1209 :: ('MESH:D020250', 'Disease') :: ['Postoperative nausea and vomiting', 'PONV']

answer: @entity619 :: (MESH:D003907,Chemical) :: ['Dexamethasone']


abstract: OBJECTIVE: To describe the association between @entity2380 and reversible @entity1665 . DESIGN: A retrospective survey of 1) @entity1 enrolled in NIAID Mycoses Study Group (MSG) protocols involving the long-term use of @entity2380 for treatment of endemic mycoses and 2) @entity1 treated with @entity2380 outside of a protocol setting but by the MSG investigators who were MSG members. SETTING: 26 MSG sites in the United States. @entity1 : 33 @entity1 with various deep and superficial mycoses who developed @entity1665 while receiving @entity2380 . RESULTS: 11 of 26 investigators reported a total of 33 @entity1 with substantial @entity1665 related to @entity2380 therapy. Underlying mycoses included @entity17101 , @entity19406 , @entity3219 , @entity1328 , @entity6656 , and @entity33 . In separate MSG studies, 17 of 136 (12.5%) and 8 of 40 (20%) @entity1 had substantial reversible @entity1665 associated with @entity2380 therapy. Eight @entity1 who were not in the protocol had similar adverse effects. Twenty-nine of 33 @entity1 (88%) received at least 400 mg of @entity2380 daily for a mean of 7.1 months. @entity1665 developed a median of 3 months after initiation of @entity2380 therapy and involved the scalp in all @entity1 . Other sites were involved in about one third of @entity1 . Three @entity1 required wigs because of extensive hair loss. @entity1665 resolved within 6 months of discontinuation of @entity2380 therapy or reduction of the daily dose by at least 50%. CONCLUSIONS: @entity1665 appears to be a common adverse event associated with higher-dose (400 mg/d) @entity2380 given for 2 months or longer. This effect may be severe but is reversed by discontinuing @entity2380 therapy or substantially reducing the daily dose.

title: XXXX associated with @entity2380 therapy.

entities_list: @entity1665 :: ('MESH:D000505', 'Disease') :: ['Alopecia', 'alopecia']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity19406 :: ('MESH:D013174', 'Disease') :: ['sporotrichosis']

entities_list: @entity2380 :: ('MESH:D015725', 'Chemical') :: ['fluconazole']

entities_list: @entity33 :: ('MESH:D052016', 'Disease') :: ['mucosal candidiasis']

entities_list: @entity17101 :: ('MESH:D001759', 'Disease') :: ['blastomycosis']

entities_list: @entity3219 :: ('MESH:D006660', 'Disease') :: ['histoplasmosis']

entities_list: @entity6656 :: ('MESH:D003047', 'Disease') :: ['coccidioidomycosis']

entities_list: @entity1328 :: ('MESH:D003453', 'Disease') :: ['cryptococcosis']

answer: @entity1665 :: (MESH:D000505,Disease) :: ['Alopecia']


abstract: BACKGROUND: @entity1 with @entity4094 often have an increased risk of @entity55 and @entity6314 , which may further be compromised by @entity1635 . @entity1635 surgery may improve pulmonary function in otherwise healthy @entity1 , but no study has evaluated its effect on the risk of @entity55 in @entity1 with @entity4094 ( @entity4094 ). METHODS: The @entity1 charts of 42 @entity1 (mean age 14.6  years) who had undergone surgery for severe @entity4094 (mean @entity1635 86  ) were retrospectively reviewed from birth to a mean of 6.1 years (range 2.8-9.5) after @entity1635 surgery. The main outcome was radiographically confirmed @entity55 as a primary cause for hospitalization. We excluded postoperative (3  months) @entity55 from the analyses. RESULTS: The lifetime annual incidence of @entity55 was 8.0/100 before and 13.4/100 after @entity1635 surgery (p  >  0.10). The mean number of hospital days per year due to @entity55 were 0.59 (SD 2.3) before @entity1635 surgery and 2.24 (SD 6.9) after surgery (p  >  0.10). Multivariate analysis demonstrated that lifetime risk factors for @entity55 were @entity302 (RR 15.2, 95  % CI 1.3-176.8, p  =  0.027), @entity306 ( @entity306 ) etiology (RR  =  10.2, 95  % CI 3.2-32.7, p  <  0.001) and major @entity1635 (main curve >70  ; RR  =  11.3, 95  % CI 1.8-70.7, p  =  0.01). CONCLUSIONS: @entity302 , non- @entity306 etiology and major @entity1635 are significant risk factors for @entity55 in @entity1 with @entity4094 . @entity1635 surgery does not decrease the incidence of @entity55 in @entity1 with severe @entity4094 . LEVEL OF EVIDENCE: Retrospective comparative study, Level III.

title: The lifetime risk of XXXX in @entity1 with @entity4094 at a mean age of 21  years: the role of spinal deformity surgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity4094 :: ('MESH:D009468', 'Disease') :: ['NMS', 'neuromuscular disorders', 'neuromuscular scoliosis']

entities_list: @entity6314 :: ('MESH:D006315', 'Disease') :: ['decreased lung function']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity1635 :: ('MESH:D012600', 'Disease') :: ['Scoliosis', 'scoliosis']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy', 'Epilepsy']

entities_list: @entity306 :: ('MESH:D002547', 'Disease') :: ['non-cerebral palsy', 'CP']

answer: @entity55 :: (MESH:D011014,Disease) :: ['pneumonia']


abstract: The purpose of this trial was to evaluate the feasibility of concurrent @entity1311 / @entity900 and conventional thoracic irradiation in locally advanced @entity1149 ( @entity1149 ). Ambulatory @entity1 with medically inoperable or unresectable stage II-III @entity1149 , and performance status 0-2 were eligible. @entity1 were not excluded from this trial if they had lost more than 5% of their body weight during the preceding 3 months, and/or if they had small ipsilateral @entity1143 . The initial dose of @entity1311 / @entity900 was 110 and 50 mg/m(2), and was escalated through five dose levels. Four cycles of chemotherapy were planned; the first two cycles were given concurrently with radiotherapy (4 weeks apart), followed by two additional cycles (every 3 weeks). Conventional chest radiotherapy to a total dose of 60 Gy (2 Gy per day) was delivered in 6 weeks. Forty-three @entity1 were enrolled of which 38 were evaluable for response. Dose-limiting @entity137 were grade 4 @entity1398 (43% of @entity1 ) and grade 3 @entity2910 (26% of @entity1 ) during the chemoradiotherapy phase. Grade > or = 2 acute and late @entity358 occurred in 10 and 68% of the @entity1 , respectively. In most @entity1 , prompt symptomatic and radiologic improvement was observed with early @entity134 administration. The volume of lung receiving 15-30 Gy was correlated with late @entity358 . The overall response was 84% with ten complete and 22 partial responses. The median survival was 16.5 months (95% confidence interval, 9.5 to 25) for those @entity1 evaluable for response. After a median follow-up of 70 months, 5 (13%) @entity1 are alive without evidence of disease. The maximum tolerated dose (MTD) of @entity1311 and @entity900 with concurrent radiotherapy is at dose level 3 @entity1311 (135 mg/m(2)) and @entity900 (75 mg/m(2)). @entity137 , although significant, was manageable in the great majority of the @entity1 . The activity observed with this regimen is particularly noteworthy when considering the advanced nature of these @entity1 , and the fact that @entity1 (N=18) with poor risk factors were included in the study.

title: Concurrent chemoradiation therapy with XXXX and @entity1311 for locally advanced @entity1149 : long-term follow-up of a phase I trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1143 :: ('MESH:D010996', 'Disease') :: ['pleural effusion']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicity', 'toxicities']

entities_list: @entity2910 :: ('MESH:D004941', 'Disease') :: ['esophagitis']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary toxicity']

answer: @entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']


abstract: Enteric administration of antigen can induce systemic tolerance. In @entity19 @entity2040 mansoni, @entity1503 produce eggs which enter the intestine. An immunologic phenomenon associated with this disease is a spontaneous diminution in the intensity of the granulomatous response in the liver, lungs, and @entity694 with @entity281 , which is termed modulation. It was determined whether modulation of liver @entity738 could be induced by enteric immunization with schistosome eggs. @entity19 infected for 4 wk were immunized by injection of 25,000 eggs into cecal pouches. This induced modulation of liver @entity738 by the eighth week of @entity281 . Neither cecal injection of normal saline nor i.p. or subcutaneous injection of eggs could induce the modulatory process. Modulation could be adoptively transferred from enterically immunized donors by injection of spleen cells into infected recipients or into uninfected recipients with synchronous liver @entity738 induced by the @entity99 of schistosome eggs. Spleen cells treated with anti- @entity3512 or anti-Lyt-1.1 and complement could no longer adoptively transfer modulation. These data show that enteric immunization with schistosome eggs can induce modulation of the @entity409 by a cellular mechanism similar to that described for the natural @entity281 .

title: Induction of @entity738 modulation in @entity19 XXXX mansoni by enteric exposure to schistosome eggs.

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic embolization']

entities_list: @entity738 :: ('MESH:D006099', 'Disease') :: ['granulomas']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver granuloma']

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['blood flukes']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'chronic infection']

entities_list: @entity2040 :: ('MESH:D012552', 'Disease') :: ['schistosomiasis']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colonic mucosa']

answer: @entity2040 :: (MESH:D012552,Disease) :: ['schistosomiasis']


abstract: There have been no reports of @entity1820 (GISTs) <20  mm with distant @entity3 . We report a case of a 15-mm @entity356 with liver @entity3 1  year after surgical resection of the @entity75 . A 35-year-old @entity1 underwent routine esophagogastroduodenoscopy in July 2009. A @entity5 ( @entity5 ) <20  mm was incidentally detected at the posterior wall of the gastric body. Endoscopic ultrasound (EUS) indicated that it was a gastrointestinal @entity361 , including GIST, @entity2909 or @entity808 . He did not accept regular follow-up for this gastric @entity5 , therefore local laparoscopic excision was carried out in October 2009. The final pathological diagnosis after surgery was GIST, 15  mm in size, and a mitotic rate of 7/50 high-power fields, which did not indicate a high metastatic risk. The @entity1 was followed up regularly without adjuvant chemotherapy. At 1  year after surgery, a space-occupying lesion ~15  mm was detected in the left lobe of the liver by abdominal ultrasound, where no @entity66 had been observed before surgery. To make a definite diagnosis of the @entity409 , EUS-guided fine-needle aspiration was performed, which demonstrated a metastatic @entity96 from a @entity356 . Although this was a rare case, we should keep in mind that gastric GISTs do have a chance of malignant behavior, even if <20  mm.

title: XXXX smaller than 20  mm with liver @entity3 .

entities_list: @entity808 :: ('MESH:D009442', 'Disease') :: ['schwannoma']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['mass lesion']

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['liver tumor']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['primary lesion']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['SMT', 'submucosal tumor']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['hepatic mass lesion']

entities_list: @entity1820 :: ('MESH:D005770', 'Disease') :: ['gastric gastrointestinal stromal tumors']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity361 :: ('MESH:C535700', 'Disease') :: ['mesenchymal tumor']

entities_list: @entity2909 :: ('MESH:D007889', 'Disease') :: ['leiomyoma']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric GIST']

answer: @entity1820 :: (MESH:D005770,Disease) :: ['Gastric gastrointestinal stromal tumor']


abstract: BACKGROUND: Exposure to @entity14911 ( @entity14912 ) may potentially disturb fetal Leydig cell hormone production and male genital development. OBJECTIVES: We aimed to study the associations between levels of amniotic fluid @entity14912 , fetal @entity479 hormone, and @entity32407 ( @entity32407 ) and the prevalence of @entity246 and @entity2650 . METHODS: Using the Danish National @entity1 Registry, we selected 270 @entity246 cases, 75 @entity2650 cases, and 300 controls with stored maternal amniotic fluid samples available in a Danish pregnancy-screening biobank (1980-1996). We used mass spectrometry to measure @entity14912 in amniotic fluid from 645 @entity1 and @entity479 hormones in samples from 545 @entity1 . @entity32407 was measured by immunoassay from 475 @entity1 . Associations between @entity14912 concentration in amniotic fluid, hormone levels, and genital @entity600 were assessed by confounder-adjusted linear and logistic regression. RESULTS: The highest tertile of @entity14912 exposure (> 1.4 ng/mL) in amniotic fluid was associated with a 40% (95% CI: -69, -11%) lower @entity32407 level and an 18% (95% CI: 7, 29%) higher @entity251 level compared with the lowest tertile (< 0.8 ng/mL). Amniotic fluid @entity14912 concentration was not associated with @entity246 or @entity2650 . CONCLUSIONS: Environmental @entity14912 exposure was associated with @entity479 hormone and @entity32407 concentrations in amniotic fluid, but was not associated with @entity246 or @entity2650 in our study population. Additional studies are needed to determine whether associations with fetal hormone levels may have long-term implications for reproductive health. Citation: Toft G, J  nsson BA, Bonde @entity6223 , N  rgaard-Pedersen B, @entity3918 , Cohen A, Lindh CH, Ivell R, Anand-Ivell R, Lindhard MS. 2016. @entity14911 concentrations in amniotic fluid, biomarkers of fetal Leydig cell function, and @entity246 and @entity2650 in Danish @entity1 (1980-1996). Environ Health Perspect 124:151-156;   http://dx.doi.org/10.1289/ehp.1409288.

title: XXXX Concentrations in Amniotic Fluid, Biomarkers of Fetal Leydig Cell Function, and @entity246 and @entity2650 in Danish @entity1 (1980-1996).

entities_list: @entity1 :: ('9606', 'Species') :: ['Patient', 'boys', 'persons']

entities_list: @entity14911 :: ('MESH:C076994', 'Chemical') :: ['perfluorooctane sulfonate', 'Perfluorooctane sulfonate']

entities_list: @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone']

entities_list: @entity2650 :: ('MESH:D007021', 'Disease') :: ['hypospadias']

entities_list: @entity246 :: ('MESH:D003456', 'Disease') :: ['cryptorchidism']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['malformations']

entities_list: @entity32407 :: ('3640', 'Gene') :: ['INSL3', 'insulin-like factor 3']

entities_list: @entity3918 :: ('MESH:D009223', 'Disease') :: ['Hougaard DM']

answer: @entity14911 :: (MESH:C076994,Chemical) :: ['Perfluorooctane Sulfonate']